PubMed Health⌕ Search

Biomedical subjects

J T Juretich

Publications and source records attributed to J T Juretich.

2 recordsLinked to original sources

Electrohydraulic ventricular assist device development.

An electrohydraulic ventricular assist device has been developed. An axial flow pump driven by a brushless DC motor provides actuation. Energy is supplied by internal Ni/Cd batteries and by external Ag/Zn batteries, both rechargeable. Electromagnetic induction is used to pass energy through the skin with a transcutaneous energy transfer (TET) system. Physiologic control, battery management, motor commutation, and communication functions are performed by a surface mount internal controller. An infrared data link within the TET coils provides bidirectional communication between the external and internal controllers. A computer model was developed to predict system performance. The dimensions are 180 mm x 116 mm x 40 mm. An in vitro system pumped 5.7 L/min at 10 mmHg inflow and 100 mmHg outflow pressure. The internal battery can provide the projected energy requirements for 40 min after 540 charge/discharge cycles, and the external battery is capable of 4 hr of operation after 150 cycles. The TET system can deliver 60 W of power and exceeds 80% efficiency between 15 and 30 W. The device configuration is based on human cadaver and intraoperative fit trials. The device is being modified for calf implantation by redirecting the blood ports, increasing the output, and incorporating the internal controller in the unified device base.

Animals↗

Preliminary in vitro evaluation of the first neonatal total artificial heart.

A neonatal total artificial heart (TAH), used as a bridging device, can offer circulatory support for patients suffering from otherwise insupportable and inoperable congenital cardiac defects. The choice of the 7.0 ml stroke volume (SV) was based on reported studies on cardiac output (CO) requirements and maximum dimensions of a neonate size TAH. This SV will allow a bridging period of up to 10 weeks in the growing neonate. For in vitro testing purposes, "high-profile" ball valves of in-house design (10-13 mm ID) were used. Redesign of the existing in vitro testing systems, including mock circulation and high-flow blood reservoirs, was required for the smaller device. Mock circulation studies (rates 90-160 BPM, full-fill and ejection modes) showed adequate device performance, with CO values well above the reported marginal output value of 139 ml/kg/min.

Heart Defects, Congenital↗